Vimta Labs Ltd Share Price

Vimta Labs Limited., established in 1984, is India's most comprehensive contract research and testing organization, providing wide range of services to pharmaceutical, biopharmaceutical, food, consumer goods, electronic, electrical, agrochemical, healthcare, medical device and many other industries. Broadly, these services include: Drug discovery, development and drug life cycle management support services in the areas like preclinical research (GLP and non-GLP), clinical research, central lab, and cGMP as well as non-GMP analytical services for pharmaceutical and biopharmaceutical companies; Preclinical research and testing services for medical device companies; Contract research and testing for Agro-science companies; Food testing and analytical development services to support manufacturers, processors, farmers, retailers, traders, exporters, regulators; Clinical diagnostics services to patients, clinicians, hospitals and Environmental regulatory services such as impact assessments and post project monitoring, to industries such as infrastructure, power, cement, oil & gas, mining etc; EMI/EMC testing for electronic and electrical products. In 1997, the Company entered into a Joint Venture with Russian Centre for Testing and Certification, ROSTEST Moscow with an investment of 24% of the total Paidup Captial. The main essence of this Joint Venture was to diversify the activities in to preshipment inspection services for all Indian exports to Russia. During 2002, the company began to offer Clinical Diagnostics Services. Clinical Specialty Diagnostics has been an internal requirement to screen the clinical trial subjects. Facilities were created in the year 2000 to speed up the clinical trials. During the year 2006-07, the Analytical and Clinical Reference Lab facilities was shifted from the existing Cherlapally Facility to the newly established Life Sciences Facility in S.P.Biotech Park, Genome Valley, Hyderabad which started commercial operations from September, 2006. During the year 2020 Company acquired 100% Equity Shares of Emtac Laboratories Private Limited, on 04th March 2020, making Emtac a wholly owned subsidiary of the Company. In 2024-25, Emtac Laboratories Pvt. Ltd., the 100% owned subsidiary got merged with the Company effective from 01 April, 2024, thereby consolidating its presence in the Electronics and Electrical testing. The Company has entered into niche segment of contract research & development of biologics and peptides in FY2025-26. The Memorandum of Association (MoA) of the Company was amended, with the Main Object Clause to undertake activities in the Biologics Contract Research and Development and Manufacturing (CDMO) segment, including contract development, analytical testing, and other R&D services relating to biologics and peptide-based drug development and manufacturing support in FY 2025-26.